Common use of Defined Term    Location Clause in Contracts

Defined Term    Location. First Collaboration Extension Term Section 2.1(d) Follow-On Product Candidate Section 5.6 HSR Act Section 5.9(a) HSR Clearance Date Section 5.9(a) HSR Filing Section 5.9(a) Implementation Date Section 5.9(a) Indemnification Claim Notice Section 11.6(c) Indemnified Party Section 11.6(c) Industry Transaction Section 13.3 Initial Collaboration Term Section 2.1(d) Initial Option Fee Section 8.4 [***] Issuing Party Section 10.3(b) JSC Section 3.2(a) Litigation Conditions Section 11.6(d)(i) Losses Section 11.6(a) [***] [***] New In-Licenses Section 4.1(a) [***] Party Preamble Patent Liaisons Section 3.3(a) Patent Committee Section 3.3(a) Phase 1 Study Data Section 5.1 Pre-IND Product Candidate Section 12.4(c) Product Candidate In-License Section 4.2 Program Directors Section 3.1 Public Offering Submission Section 6.6 Receiving Party Section 10.1(a) Release Section 10.3(b) [***] Reviewing Party Section 10.3(b) Second Collaboration Extension Term Section 2.1(d) Securities Act Section 6.6 [***] Sub-Committees Section 3.2(c)(xi) Term Section 12.1 Third Party Claims Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Defined Term    Location. First Collaboration Extension Term Accurin™ Class Specific Data Section 2.1(d8.3(a) Follow-On Product Candidate Affected Party Section 5.6 HSR Act 15.2(d) Alliance Manager Section 5.9(a3.2(f) HSR Clearance Date Amgen Preamble Amgen Core IP Section 5.9(a10.2(a) HSR Filing Amgen Indemnitees Section 5.9(a14.6(c) Implementation Date Amgen Option Period Section 5.9(a) Indemnification Claim 4.1 Amgen Option Notice Section 11.6(c4.1 Amgen Program IP Section 10.2(b) Indemnified Party Associates or Associate Section 11.6(c8.7(c) Industry Transaction Bankruptcy Event Section 13.3 Initial 15.2(d) BIND Preamble BIND Core IP Section 10.2(a) BIND Indemnitees Section 14.6(a) BIND License Option Notice Section 4.2 BIND Program IP Section 10.2(c)(i) Amgen Contract No.: 2013579490 8 EXECUTION COPY Claim Section 14.6(d) Competitive Infringement Section 12.1 Confidential Information Section 13.1(a) Design/Preclinical Collaboration Plan Section 2.1 Design/Preclinical Collaboration Term Section 2.1(d2.1 Disclosing Party Section 13.1(a) Effective Date Preamble Exclusivity Lapse Period Section 9.6(b) Extended Exclusivity Notice Section 7.2 Extended Exclusivity Period Section 7.2 First Product Candidate or Licensed Product Section 9.3 Indemnitee Section 14.6(d) Indemnitor Section 14.6(d) Initial Exclusivity Period Section 7.1 Issuing Party Section 13.2(b) JRC Section 3.2 Joint Program IP Section 10.2(c)(i) Losses Section 14.6(a) Milestone Bearing Product Candidate or Licensed Product Section 9.3 Option Fee Section 8.4 [***] Issuing 9.2 Party Section 10.3(b) JSC Section 3.2(a) Litigation Conditions Section 11.6(d)(i) Losses Section 11.6(a) [***] [***] New In-Licenses Section 4.1(a) [***] Party or Parties Preamble Patent Liaisons Section 3.3(a) Patent Committee Section 3.3(a) Phase 1 Study Data Section 5.1 Pre-IND Product Candidate Claim Section 12.4(c10.2(a) Product Candidate In-License Specific Patent Section 4.2 11.1(c) Program Directors Lead Section 3.1 Public Offering Submission Section 6.6 Receiving Party Section 10.1(a13.1(a) Release Section 10.3(b13.2(b) [***] Reviewing Party Section 10.3(b13.2(b) Second Collaboration Extension Term Product Candidate or Licensed Product Section 2.1(d) Securities Act 9.3 Skipped Milestone Event Section 6.6 [***] Sub-Committees 9.3 Sole Program IP Section 3.2(c)(xi10.2(c) Term Section 12.1 Third Party Claims Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.15.1

Defined Term    Location. First Collaboration Extension Term Act Preamble Bona Fide Offer Section 2.1(d6.3(a) Follow-On Product Candidate Capital Account Section 5.6 HSR Act Section 5.9(a3.8(a) HSR Clearance Closing Date Section 5.9(a6.3(e) HSR Filing Company Preamble Damages Section 5.9(a5.7 Declining Member Section 3.10 Disposing Member Section 6.4(b) Implementation Effective Date Section 5.9(a4.1(b) Indemnification Claim Encumber Section 6.1 First Refusal Election Notice Section 11.6(c6.3(a) Indemnified Party First Refusal Offer Section 11.6(c6.3(a) Industry Transaction First Refusal Right Section 13.3 Initial Collaboration Term 6.3(b) First Repurchase Event Option Section 2.1(d6.4(c)(ii) First Repurchase Event Option Period Section 6.4(c)(ii) Gross Asset Value Section 3.8(d) Identifying Member Section 5.8(b) Initial Option Fee Capital Contributions Section 8.4 [***] Issuing Party 1.1(xvii) Investment Capital Section 10.3(b) JSC 3.10 Loan Request Section 3.2(a) Litigation Conditions Maker Section 11.6(d)(i6.3(c) Losses Member Nonrecourse Deductions Section 11.6(a4.2(c)(iii) [***] [***] New In-Licenses Member Preamble Member Loan Section 4.1(a3.2(a) [***] Party Offered Interests Section 6.4(a) Offeree Section 6.4(a) Offering Member Section 6.3(a) Operating Agreement Preamble Patent Liaisons Option Termination Date Section 3.3(a6.3(d) Patent Committee Permitted Transferee Section 3.3(a6.2(d) Phase 1 Study Data Purchase Price Section 5.1 Pre-IND Product Candidate 6.4(d) Repurchase Event Option Notice Section 12.4(c6.4(c)(i) Product Candidate In-License Repurchaser Event Election Notice Section 4.2 Program Directors 6.4(c)(ii) Repurchase Event Options Section 3.1 Public Offering Submission Section 6.6 Receiving Party Section 10.1(a) Release Section 10.3(b) [***] Reviewing Party Section 10.3(b6.4(c)(iii) Second Collaboration Extension Term Repurchase Event Option Section 2.1(d6.4(c)(iii) Securities Act Second Repurchase Event Options Period Section 6.6 [***] Sub-Committees 6.4(c)(iii) Selling Member Section 3.2(c)(xi6.4(a) Term Terms Section 12.1 Third Party Claims 5.8(b) TMP Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.7.6 Transfer Section 6.i Transferring Members Section 6.4(a)

Defined Term    Location. First Collaboration Extension Term Agreement Introductory Paragraph Banking Day Section 2.1(d3 Base Rate Section 4(A)(1) Follow-On Product Candidate Borrower Introductory Paragraph Business Day Section 5.6 HSR Act 3 Capital Lease Section 5.9(a14(A) HSR Clearance CoBank Introductory Paragraph Commission Section 13(I)(6) Companies Section 13(I)(1) Consolidated Basis Section 13(I)(1) CTE Section 13(I)(9) Default Section 11(I) Equity to Total Capitalization Ratio Section 13(J)(3) Event of Default Section 15 Factual Matters Certificate Section 11(N) FCC Section 13(I)(6) Federal Funds Rate Section 4(A)(I) Funding Date Section 5.9(a3 GAAP Section 12(H) HSR Filing Governmental Authority Section 5.9(a16(E) Implementation Indebtedness Section 13(J)(1) Interest Coverage Ratio Section 13(J)(2) Interest Period Section 4(A)(2)(a) Investment Section 14(E) Laws Section 12(E) LIBOR Section 4(A)(2)(a) LIBOR Rate Section 4(A)(2)(a) Loan Section 1 Loan Documents Section 11(A) Material Adverse Change Section 11(K) Maturity Date Section 5.9(a5 National Variable Rate Section 4(A)(1) Indemnification Claim Notice Note Section 11.6(c7 Operating Cash Flow Section 13(J)(1) Indemnified Party Payment Date Section 11.6(c5 Portion Section 4(A)(1) Industry Transaction Prior Agreement Preamble Rating Agency Section 13.3 Initial Collaboration Term 14(E) SEC Section 2.1(d13(I)(6) Initial Option Fee Surcharge Section 8.4 [***] Issuing Party 6 Total Leverage Ratio Section 10.3(b) JSC Section 3.2(a) Litigation Conditions Section 11.6(d)(i) Losses Section 11.6(a) [***] [***] New In-Licenses Section 4.1(a) [***] Party Preamble Patent Liaisons Section 3.3(a) Patent Committee Section 3.3(a) Phase 1 Study Data Section 5.1 Pre-IND Product Candidate Section 12.4(c) Product Candidate In-License Section 4.2 Program Directors Section 3.1 Public Offering Submission Section 6.6 Receiving Party Section 10.1(a) Release Section 10.3(b) [***] Reviewing Party Section 10.3(b) Second Collaboration Extension Term Section 2.1(d) Securities Act Section 6.6 [***] Sub-Committees Section 3.2(c)(xi) Term Section 12.1 Third Party Claims Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.13(J)(1)

Defined Term    Location. First Collaboration Extension Term Company Termination Date Section 2.1(d8.1(b) Follow-On Product Candidate Company Welfare Plans Section 5.6 5.11(c) Company 401(k) Plan Section 5.11(e) Confidentiality Agreement Section 5.4(b) Continuing Employees Section 5.11(a) Delaware Secretary of State Section 1.3 Derivative Transactions Section 3.24 DGCL Section 1.1 DLLCA Section 1.1 DOL Section 3.14(c)(i) Effective Time Section 1.3 Election Deadline Section 2.1(d)(ii) Election Form Section 2.1(d)(i) Election Form Record Date Section 2.1(d)(i) Employment and Withholding Taxes Section 8.5(d)(vi) Environmental Laws Section 3.18(a) ERISA Section 3.14(a) Exchange Act Section 3.5(b) Exchange Agent Section 2.4(a) Exchange Fund Section 2.4(a) Exchange Ratio Section 2.1(b)(iii) Excluded Shares Section 2.1(f) FCPA Section 3.7(b) FTC Section 5.5(b) Governmental Entity Section 3.5(a) Governmental Foreign Plan Section 3.14(n) Hazardous Material Section 8.5(d)(vii) HSR Act Section 5.9(a3.5(b) HSR Clearance Intellectual Property Section 8.5(d)(viii) In-the-Money Company Options Section 2.3(a) IRS Section 3.14(c)(i) knowledge Section 8.5(d)(ix) Law Section 8.5(d)(x) Liens Section 8.5(d)(xi) Litigation Section 8.5(d)(xii) Mailing Date Section 5.9(a2.1(d)(i) HSR Filing Material Adverse Effect Section 5.9(a8.5(d)(xiii) Implementation Date Merger Preamble Merger Consideration Section 5.9(a2.1(e) Indemnification Claim Notice Merger Sub Preamble Mixed Consideration Election Share Section 11.6(c2.1(b)(i) Indemnified Party Mixed Election Stock Exchange Ratio Section 11.6(c2.1(b)(i) Industry Transaction Money Laundering Laws Section 13.3 Initial Collaboration Term 3.7(c) Non-Election Shares Section 2.1(d2.1(d)(ii) Initial Option Fee NYSE Section 8.4 [***] Issuing Party Section 10.3(b) JSC Section 3.2(a) Litigation Conditions Section 11.6(d)(i) Losses Section 11.6(a) [***] [***] New In-Licenses Section 4.1(a) [***] Party Preamble Patent Liaisons Section 3.3(a) Patent Committee Section 3.3(a) Phase 1 Study Data Section 5.1 Pre-IND Product Candidate Section 12.4(c) Product Candidate In-License Section 4.2 Program Directors Section 3.1 Public Offering Submission Section 6.6 Receiving Party Section 10.1(a) Release Section 10.3(b) [***] Reviewing Party Section 10.3(b) Second Collaboration Extension Term Section 2.1(d) Securities Act Section 6.6 [***] Sub-Committees Section 3.2(c)(xi) Term Section 12.1 Third Party Claims Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.2.1(b)(i)

Defined Term    Location. First Collaboration Extension Term Out-of-Pocket Expenses Section 2.1(d8.1(c) Follow-On Product Candidate Parent Preamble Parent Common Stock Section 5.6 HSR Act 2.1(b)(i) Parent DC Plan Section 5.9(a5.11(e) HSR Clearance Date Section 5.9(a) HSR Filing Section 5.9(a) Implementation Date Section 5.9(a) Indemnification Claim Notice Section 11.6(c) Indemnified Party Section 11.6(c) Industry Transaction Section 13.3 Initial Collaboration Term Section 2.1(d) Initial Option Fee Section 8.4 [***] Issuing Party Section 10.3(b) JSC Section 3.2(a) Litigation Conditions Section 11.6(d)(i) Losses Section 11.6(a) [***] [***] New In-Licenses Section 4.1(a) [***] Party Preamble Patent Liaisons Section 3.3(a) Patent Committee Section 3.3(a) Phase 1 Study Data Section 5.1 Pre-IND Product Candidate Section 12.4(c) Product Candidate In-License Parent Disclosure Letter Article IV Parent Governing Documents Section 4.2 Program Directors Parent Options Section 3.1 Public Offering Submission 4.3 Parent Preferred Stock Section 6.6 Receiving Party 4.3 Parent SEC Documents Section 10.1(a4.7(a) Parent Share Value Section 2.1(b)(i) Parent Subsidiaries Section 4.1 PBGC Section 3.14(f) Per Share Cash Election Consideration Section 2.1(b)(ii) Per Share Mixed Consideration Section 2.1(b)(i) Per Share Mixed Election Cash Amount Section 2.1(b)(i) Per Share Mixed Election Stock Amount Section 2.1(b)(i) Per Share Stock Election Consideration Section 2.1(b)(iii) Permits Section 3.6(b) Permitted Liens Section 8.5(d)(xiv) Person Section 8.5(d)(xv) Proxy Statement Section 3.15 Recent Company SEC Documents Section 3.9 Registered IP Section 3.23(a) Registration Statement Section 3.15 Release Section 10.3(b8.5(d)(xvi) [***] Reviewing Party Representatives Section 10.3(b5.3(a) Second Collaboration Extension Term Return Section 2.1(d8.5(d)(xvii) SEC Section 3.8(a) Securities Act Section 6.6 [***] 3.5(b) SOX Section 3.21(a) Stock Election Share Section 2.1(b)(iii) Stock Plans Section 2.3(a) Subsidiary Section 8.5(d)(xviii) Superior Proposal Section 5.3(e) Surviving Entity Section 1.1 Tax Section 8.5(d)(xix) Termination Date Section 7.1(b)(i) Title IV Plan Section 3.14(b) USG Authorities Section 5.5(f) WARN Act Section 3.19(c) Welfare Plan Section 3.14(j) This Agreement and Plan of Merger (this “Agreement”) dated April 9, 2010, by and among Halliburton Company, a Delaware corporation (“Parent”), Gradient, LLC, a Delaware limited liability company and a wholly-owned Subsidiary of Parent (“Merger Sub-Committees Section 3.2(c)(xi) Term Section 12.1 Third Party Claims Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH ”), and Boots & ▇▇▇▇▇, Inc., a Delaware corporation (the “[***]Company”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED).

Defined Term    Location. First Collaboration Extension Term Control Section 2.1(d) Follow-On 1.22 Covers Section 1.23 Declined Product Candidate Section 5.6 5.6(a) Development Section 1.24 Development & Commercialization Agreements Section 1.25 Disclosing Party Section 8.1(a) DOJ Section 5.8(b) Effective Date Preamble Elected Candidate Section 5.2 EMA Section 1.26 FDA Section 1.27 Field Section 1.28 Financial Investor Section 1.9 FTC Section 5.8(b) HSR Act Section 5.9(a5.8(b) HSR Clearance Date Section 5.9(a5.8(b) HSR Filing Section 5.9(a5.8(b) Implementation Date Section 5.9(a5.8(b) IND Section 1.29 Indemnification Claim Notice Section 11.6(c9.6(c) Indemnified Party Section 11.6(c) Industry Transaction Section 13.3 Initial Collaboration Term Section 2.1(d9.6(c) Initial Option Fee Section 6.2 Initial Primary Analysis Section 1.48 Issuing Party Section 8.3(b) JSC Section 3.2(a) Know-How Section 1.31 Knowledge Section 1.32 Law Section 1.33 Lead Product Candidate Section 1.34 license Section 1.35 License Agreement Section 1.25 Litigation Conditions Section 9.6(d)(i) Losses Section 9.6(a) MAA Section 1.38 Manufacturing Section 1.36 Materials Section 1.37 Mutual Confidentiality Agreement Section 8.4 New In-Licenses Section 4.1(a) Next Generation Product Candidate Section 1.39 [***] Issuing Option Fee Section 1.41 Optioned Candidate Section 1.42 Original Agreement Preamble Original Agreement Date Preamble Other In-License Section 1.43 Party(ies) Preamble Patent Section 1.44 Patent Costs Section 1.45 Patent Liaisons Section 3.3(a) Patent Committee Section 3.3(a) Payload Section 1.46 Person Section 1.47 Phase 1 Study Section 1.48 Phase 2/3 Study Section 1.49 Phase 3 Study Section 1.50 Pre-Existing In-License Section 1.51 Product Candidate Section 1.52 Product Candidate In-License Section 4.2 Program Directors Section 3.1 Prosecution and Maintenance Section 1.53 Receiving Party Section 10.3(b8.1(a) JSC Release Section 3.2(a8.3(b) Litigation Conditions Regulatory Approval Section 11.6(d)(i1.54 Regulatory Authority Section 1.55 Regulatory Data Section 1.56 Regulatory Filing Section 1.57 Reviewing Party Section 8.3(b) Losses SEC Section 11.6(a8.3(d) Sub-Committees Section 3.2(c)(x) Target Antigen Section 1.58 T-Cell Section 1.59 Term Section 10.1 Third Party Section 1.60 Third Party Claims Section 9.6(a) [***] [***] New In-Licenses United States (U.S.) Section 4.1(a) [***] Party Preamble Patent Liaisons 1.63 Vector Section 3.3(a) Patent Committee Section 3.3(a) Phase 1 Study Data Section 5.1 Pre-IND Product Candidate Section 12.4(c) Product Candidate In-License Section 4.2 Program Directors Section 3.1 Public Offering Submission Section 6.6 Receiving Party Section 10.1(a) Release Section 10.3(b) [***] Reviewing Party Section 10.3(b) Second Collaboration Extension Term Section 2.1(d) Securities Act Section 6.6 [***] Sub-Committees Section 3.2(c)(xi) Term Section 12.1 Third Party Claims Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.1.64

Defined Term    Location. First Collaboration Extension Term Section 2.1(dEnvironmental Permits ‎Section 3.16(e)(iii) Follow-On Product Candidate Section 5.6 HSR Act Section 5.9(aERISA ‎Section 3.11(a) HSR Clearance Date Section 5.9(aExchange Agent ‎Section 2.02(a) HSR Filing Section 5.9(aExchange Fund ‎Section 2.02(a) Implementation Date Section 5.9(aExcluded Shares ‎Section 2.01(a)(ii) Indemnification Claim Excluded Transaction ‎Section 5.05(c) FBB Preamble FBB Benefit Plan ‎Section 4.10(a) FBB Board Recitals FBB Capital Stock ‎Section 4.02(a)(i) FBB Employees ‎Section 4.11(a) FBB Equity Awards ‎Section 4.02(a)(i) FBB Financial Statements ‎Section 4.05(a) FBB IP Rights ‎Section 4.19(a) FBB Leased Real Property ‎Section 4.21(b) FBB Licenses ‎Section 3.14(a) FBB Material Contract ‎Section 4.14(a) FBB Nominee Directors ‎Section 6.09(a) FBB Owned Real Property ‎Section 4.21(a) FBB Real Property Lease ‎Section 4.21(b) FBB Restricted Stock Awards ‎Section 4.02(a)(i) FBB Selling Stockholders ‎Section 6.02(a) FBB Stockholder Approval ‎Section 4.03(a) FBB Stockholder Notice Section 11.6(c‎Section 6.01(d) FBB Takeover Proposal ‎Section 5.05(b) FBB Voting Debt ‎Section 4.02(b) FBB Written Consent ‎Section 6.01(c) FBB’s Financial Advisor ‎Section 4.06 Final Stockholders Registry ‎Section 2.02(a) FLSA ‎Section 3.12(a) GAAP ‎Section 3.06(a) Governmental Entity ‎Section 3.04 Hazardous Materials ‎Section 3.16(e)(iv) Indemnified Party Section 11.6(c‎Section 6.02(g) Industry Transaction Section 13.3 Initial Collaboration Term Section 2.1(dIndependent Director ‎Section 6.09(a) Initial Option Fee Section 8.4 [***] Issuing Party Section 10.3(bInformation Statement ‎Section 6.01(e) JSC Section 3.2(aInjunction ‎Section 3.03(c) Litigation Conditions Section 11.6(d)(iIntended Tax Treatment Recitals Law ‎Section 3.14(a) Losses Section 11.6(aLicenses ‎Section 3.14(a) [***] [***] Lien ‎Section 3.03(c) Merger ‎Section 1.01 Merger Consideration ‎Section 2.01(a)(i) Merger Sub Preamble Multiemployer Plan ‎Section 3.11(a) Nasdaq ‎Section 3.04 New In-Licenses Section 4.1(aBenefit Plan ‎Section 6.10(b) [***] Party Preamble Patent Liaisons Section 3.3(aNew Plan ‎Section 6.10(c) Patent Committee Section 3.3(aNotice of DXL Adverse Recommendation Change ‎Section 5.06(f) Phase 1 Study Data Section 5.1 Pre-IND Product Candidate Section 12.4(c) Product Candidate In-License Section 4.2 Program Directors Section 3.1 Public Offering Submission Section 6.6 Receiving Party Section 10.1(a) Release Section 10.3(b) [***] Reviewing Party Section 10.3(b) Second Collaboration Extension Term Section 2.1(d) Securities Act Section 6.6 [***] Sub-Committees Section 3.2(c)(xi) Term Section 12.1 Third Party Claims Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.-86-

Defined Term    Location. First Collaboration Extension Term Enlivex Termination Fee Section 2.1(d6.08(c) FollowEnlivex Warrants Section 4.02(a)(i) Environmental Claims Section 3.15(e)(i) Environmental Laws Section 3.15(e)(ii) Environmental Permits Section 3.15(e)(iii) ERISA Section 3.11(b) Exchange Agent Section 2.02(a) Exchange Ratio Section 2.01(b)(i) FDA Section 3.21(b) FDCA Section 3.21(b) Final Shareholders Registry Section 2.02(a) Governmental Entity Section 3.04 Governmental Grant Section 3.26 Hazardous Materials Section 3.15(e)(iv) Health Care Law Section 3.21(b) IIA Notice Section 6.17 Indemnified Person Section 6.12(a) Injunction Section 3.03(c) Intended Tax Treatment Recitals Israeli Registrar of Companies Section 1.03 Israeli Tax Ruling Section 2.02(h)(ii) Law Section 3.13(a) Licenses Section 3.13(a) Lien Section 3.01(b)(ii) Merger Section 1.01 Merger Consideration Section 2.01(a) Merger Proposal Section 6.04 Merger Shares Section 2.01(b)(ii) Merger Sub Preamble Nasdaq Section 3.04 Notice of Bioblast Adverse Recommendation Change Section 5.06(f) Notice of Enlivex Adverse Recommendation Change Section 5.05(f) Payor Section 2.02(h)(i) PHSA Section 3.21(b) Proxy Statement Section 3.04 Regulatory Agencies Section 3.05 Release Section 3.15(e)(v) Required Bioblast Shareholder Vote Section 3.03(b) Reverse Split Section 5.02(c) S▇▇▇▇▇▇▇-On Product Candidate Section 5.6 HSR ▇▇▇▇▇ Act Section 5.9(a3.06(f) HSR Clearance Date Section 5.9(a102 Option Consideration Section 2.02(g) HSR Filing Surviving Company Section 5.9(a1.01 Surviving Company Articles Section 1.05 Takeover Statute Section 3.16 Valid Certificate Section 2.02(h)(i) Implementation Date VAT Section 5.9(a3.10(x) Indemnification Claim Notice Section 11.6(c) Indemnified Party Section 11.6(c) Industry Transaction Section 13.3 Initial Collaboration Term Section 2.1(d) Initial Option Fee Section 8.4 [***] Issuing Party Section 10.3(b) JSC Section 3.2(a) Litigation Conditions Section 11.6(d)(i) Losses Section 11.6(a) [***] [***] New In-Licenses Section 4.1(a) [***] Party Preamble Patent Liaisons Section 3.3(a) Patent Committee Section 3.3(a) Phase 1 Study Data Section 5.1 Pre-IND Product Candidate Section 12.4(c) Product Candidate In-License Section 4.2 Program Directors Section 3.1 Public Offering Submission Section 6.6 Receiving Party Section 10.1(a) Release Section 10.3(b) [***] Reviewing Party Section 10.3(b) Second Collaboration Extension Term Section 2.1(d) Securities Act Section 6.6 [***] Sub-Committees Section 3.2(c)(xi) Term Section 12.1 Third Party Claims Section 11.6(a) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.Voting Agreement Recitals